Sign Up
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

NICE (UK) positive for Imfinzi (durvalumab) with Imjudo (tremelimumab) for untreated advanced or unresectable hepatocellular carcinoma – AstraZeneca

Written by | 2 Sep 2025 | Hepatology

NICE(UK): Durvalumab with tremelimumab can be used, within its marketing authorisation, as an option for untreated advanced or unresectable hepatocellular carcinoma (HCC) in adults. Durvalumab with tremelimumab can only be used if the company provides it according to the commercial arrangement.

Why the committee made this recommendation: Usual treatment for untreated advanced or unresectable HCC includes atezolizumab with bevacizumab, or lenvatinib or sorafenib alone. Most people have atezolizumab with bevacizumab. Evidence from a clinical trial suggests that durvalumab with tremelimumab increases how long people live compared with sorafenib. Indirect comparisons suggest that durvalumab with tremelimumab is likely to work as well as atezolizumab with bevacizumab, and that is likely to increase how long people live compared with lenvatinib. The most likely cost-effectiveness estimates are within the range that NICE normally considers an acceptable use of NHS resources compared with some of the usual treatments. So, durvalumab with tremelimumab can be used.

Newsletter Icon

Register for our mailing list

If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.

Sign Up

You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.